Sections View Full Chapter Figures Tables Videos Annotate Full Chapter Figures Tables Videos Supplementary Content +++ INTRODUCTION ++ Epidemiology Table Graphic Jump Location|Download (.pdf)|Print Epidemiology Incidence: 23,890 (male: 13,590; female: 10,300. Estimated new cases for 2020 in the United States) 7.5 per 100,000 men vs Male 5.4 per 100,000 women vs Female Deaths: Estimated 18,020 in 2020 (male: 10,190; Female vs female: 7830) Median age at diagnosis: 59 years Male to female ratio: Slight male predominance in the incidence of malignant brain tumors (Male:Female 1.39:1) Siegel R et al. CA Cancer J Clin 2020;70:7–30 Surveillance, Epidemiology and End Results (SEER) Program, available from http://seer.cancer.gov [accessed in 2020] ++ Work-up Neuroimaging study (MRI of the brain preferred over CT) No other staging work-up is required except: Primary CNS lymphoma: MRI of spine, lumbar puncture, and ophthalmologic examination Medulloblastoma: MRI of spine and lumbar puncture when safe to do so ++ Pathology Neuroepithelial Tumors Glial tumors (45–50%) Diffuse astrocytic tumors (75%) Diffuse astrocytoma (grade II): 20% Diffuse astrocytoma, IDH-mutant Gemistocytic astrocytoma, IDH-mutant Diffuse astrocytoma, IDH-wildtype Anaplastic astrocytoma (AA grade III): 30% Anaplastic astrocytoma, IDH-mutant Anaplastic astrocytoma, IDH-wildtype Glioblastoma (GB, grade IV): 50% Glioblastoma, IDH-wildtype Giant cell glioblastoma Gliosarcoma: <5% of GB Epithelioid glioblastoma Glioblastoma, IDH-mutant Diffuse midline glioma H3 K27M-mutant (grade IV) Oligodendrogliomas/oligoastrocytomas (5–10%) Oligodendroglioma (O, grade II) Oligodendroglioma, IDH-mutant, 1p19q-codeleted Anaplastic oligodendroglioma (AO, grade III) Anaplastic oligodendroglioma, IDH-mutant, 1p19q-codeleted Oligoastrocytoma (OA, grade II) Oligoastrocytoma NOS (Most OA will fall into this category if molecular testing for oligodendroglioma and astrocytoma is not diagnostic) Oligoastrocytoma (IDH-mutant, 1p19q-codeleted on oligodendroglioma side, IDH-mutant vs wildtype, 1p19q-intact on astrocytoma side) Anaplastic oligoastrocytoma (AOA grade III) Anaplastic oligoastrocytoma NOS (Most AOA will fall into this category if molecular testing for oligodendroglioma or astrocytoma is not diagnostic) Anaplastic oligoastrocytoma (IDH mutant, 1p19q-codeleted on oligodendroglioma side, IDH-mutant vs wildtype, 1p19q-intact on astrocytoma side) Other astrocytic tumors (<5%) Pilocytic astrocytoma (grade I) Subependymal giant cell astrocytoma (grade I) Pleomorphic xanthoastrocytoma (grade II) Anaplastic pleomorphic xanthoastrocytoma (grade III) Ependymal tumors (5%) Subependymoma (grade I) Myxopapillary ependymoma (grade I) Ependymoma (grade II) Papillary ependymoma Clear cell ependymoma Tanycytic ependymoma Ependymoma. RELA fusion-positive (grade II or III) Anaplastic ependymoma (grade III) Neuronal and mixed glial-neuronal tumors (<1%) Central neurocytoma (grade II) Dysembryoplastic neuroepithelial tumor (DNET) (grade I) Desmoplastic infantile astrocytoma and ganglioglioma (grade I) Gangliocytoma (grade I) Ganglioglioma (grade I) Anaplastic ganglioglioma (grade III) Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos disease) (grade I) Paraganglioma Nonglial tumors Embryonal tumors (<5%) Medulloblastoma (grade IV) Medulloblastoma, WNT-activated Medulloblastoma, SHH activated and TP53-mutant Medulloblastoma, SHH activated and TP53-wildtype Medulloblastoma, non-WNT/non-SHH Medulloblastoma group 3 Medulloblastoma group 4 CNS neuroblastoma (grade IV) Atypical teratoid/rhabdoid tumors (AT/RT) (grade IV) Choroid plexus tumors (<1%) Choroid plexus papilloma (grade I) Atypical choroid plexus papilloma (grade II) Choroid plexus carcinoma (grade III) Pineal tumors (<1%) Pineocytoma (grade I) Pineoblastoma (grade IV) Meningeal Tumors (15–28%) Meningioma (grade I): (>80–90%) Secretory meningioma (grade I) Fibrous meningioma (grade I) Atypical meningioma (grade II): (10–20%) Clear cell meningioma (grade II) Chordoid meningioma (grade II) Anaplastic (malignant) meningioma (grade III): ... Your Access profile is currently affiliated with [InstitutionA] and is in the process of switching affiliations to [InstitutionB]. Please select how you would like to proceed. Keep the current affiliation with [InstitutionA] and continue with the Access profile sign in process Switch affiliation to [InstitutionB] and continue with the Access profile sign in process Get Free Access Through Your Institution Learn how to see if your library subscribes to McGraw Hill Medical products. Subscribe: Institutional or Individual Sign In Error: Incorrect UserName or Password Username Error: Please enter User Name Password Error: Please enter Password Sign in Forgot Password? Forgot Username? Sign in via OpenAthens Sign in via Shibboleth You already have access! Please proceed to your institution's subscription. Create a free profile for additional features.